NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
I-Mab Biopharma US Limited
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC
Xencor, Inc.
Incyte Corporation
Genentech, Inc.
Novartis
TransThera Sciences (Nanjing), Inc.
Exelixis
Stanford University
Compugen Ltd
Cyteir Therapeutics, Inc.
Sellas Life Sciences Group
Vincerx Pharma, Inc.
Hutchmed
Cantargia AB
Xencor, Inc.
Amgen
TransThera Sciences (Nanjing), Inc.
Eli Lilly and Company
Corvus Pharmaceuticals, Inc.
Tempest Therapeutics
Xencor, Inc.
Nektar Therapeutics
Novartis
Corcept Therapeutics
Xencor, Inc.
Incyte Corporation
Bayer
AbbVie
AbbVie
Novartis
Incyte Corporation
Incyte Corporation
Gilead Sciences
Novartis
Bristol-Myers Squibb
AstraZeneca
Novartis
Novartis
Incyte Corporation
Pfizer
Array BioPharma
AstraZeneca
Ipsen
Celgene
National Cancer Institute (NCI)
Merrimack Pharmaceuticals